ArticleInternational journal of colorectal disease2025
Standard of practice imaging vs. PET/MR: a comparative prospective study in rectal cancer staging.
Article in International journal of colorectal disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical utility and future directions of FDG-PET in rectal cancer management.Annals of nuclear medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundRectal cancer (RC) remains a significant global health concern, with increasing incidence rates and associated mortality. Early detection of metastases plays a crucial role in the effective management of rectal cancer and predicting patient outcomes. Imaging modalities are vital in diagnosing and evaluating the extent of metastases. The integration of novel hybrid positron emission tomography utilizing fluorodeoxyglucose (18F-FDG) fused with magnetic resonance (PET/MR) has emerged as an innovative diagnostic tool. By combining both technologies' strengths, PET/MR imaging provides precise metabolic information from PET alongside detailed anatomical data from MR. This prospective study aimed to assess the clinical utility of PET/MR imaging with the 18F-FDG tracer compared to standard imaging modalities for detecting the extent of RC.
methodsWe enrolled 42 patients who underwent both standard imaging (CT and/or MRI) and whole-body PET/MR with 18F-FDG before preoperative therapy.
resultsOur results indicated that PET/MR with 18F-FDG provides superior detection of lymph nodes and tumor deposits in the mesorectum, with the highest diagnostic accuracy for tumor length measurement (area under the ROC curve (AUC) = 0.730; p < 0.05) and a combined model of SUVmax and CEA (AUC = 0.921; p < 0.001). Furthermore, PET/MR changed the clinical stage in 64% of patients and altered clinical management in 26% of cases.
conclusionsThe presented findings demonstrate the effectiveness of this advanced imaging technique and its potential to enhance treatment planning. By providing more accurate staging information, this method could significantly improve diagnosis, treatment customization, and overall outcomes for patients with rectal cancer, particularly in cases where lymph node involvement and tumor deposits impact therapeutic decisions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.